Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)
Hong Kong
· Delayed Price · Currency is HKD 17.25
-0.55 (-3.09%)
Mar 10, 2026, 11:49 AM HKT
Hanx Biopharmaceuticals (Wuhan) Company Description
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. develops and manufactures immunotherapies for cancer and autoimmune diseases.
The company's products include antibody drugs, including monoclonal, bispecific, and antibody drug conjugates for immuno-oncology pathways.
The company was incorporated in 2014 and is headquartered in Wuhan, China.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
| Country | China |
| Founded | 2014 |
| Industry | Marine Shipping |
| Sector | Industrials |
| Employees | 55 |
| CEO | Qixiang Li |
Contact Details
Address: Building A8, Phase II Wuhan China | |
| Phone | 86 27 6552 4978 |
| Website | hanxbio.com |
Stock Details
| Ticker Symbol | 3378 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000004N5 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Liqun Cai | Executive Chairman |
| Zhaohui Chen | GM and Executive Director |
| Zhen Chen | Chief Financial Officer, Deputy GM and Executive Director |
| Fuguang Lin | Executive Director |
| Yan Song Wu | Deputy General Manager |
| Changzhen Cai | Company Secretary |
| Yanping Song | Chief Accountant |
| Yibing Zhang | Head of Finance Department |